Sectors
CRBP
Corbus Pharmaceuticals Holdings, Inc.
9.62
3 x 9.21
1 x 9.64
bid
ask
+
0.16
1.72%
09:40 AM
timesize
| Ytd | 18.22% | |
| 1y | 10.99% |
9.50
day range
9.70
7.12
52 week range
20.56
| Open | 9.54 | Prev Close | 9.46 | Low | 9.50 | High | 9.70 | Mkt Cap | 177.89M |
| Vol | 7.35K | Avg Vol | 480.92K | EPS | -5.82 | P/E | -1.65 | Forward P/E | -2.51 |
| Beta | 2.59 | Short Ratio | 8.28 | Inst. Own | 105.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.72 | 200-d Avg | 9.54 | 1yr Est | 56.78 |
| Income Statement | |||
| Operating Expenses | 36.19M | ||
| Research and Development Expense | 31.18M | ||
| Selling, General and Administrative Expense | 5.01M | ||
| Operating Income | -36.19M | ||
| Net Income | -35.04M | ||
| Net Income Common Stock | -35.04M | ||
| Net Income Common Stock (USD) | -35.04M | ||
| Consolidated Income | -35.04M | ||
| Earnings per Basic Share | -1.81 | ||
| Earnings per Basic Share (USD) | -1.81 | ||
| Earnings per Diluted Share | -1.81 | ||
| Earning Before Interest & Taxes (EBIT) | -35.04M | ||
| Earning Before Interest & Taxes (USD) | -35.04M | ||
| Weighted Average Shares | 19.41M | ||
| Weighted Average Shares Diluted | 19.41M | ||
| Balance Sheet | |||
| Cash and Equivalents | 23.76M | ||
| Cash and Equivalents (USD) | 23.76M | ||
| Investments | 94.57M | ||
| Investments Current | 94.57M | ||
| Current Assets | 122.75M | ||
| Property, Plant & Equipment Net | 3.85M | ||
| Total Assets | 126.99M | ||
| Debt Current | 999.00K | ||
| Total Debt | 4.26M | ||
| Current Liabilities | 21.48M | ||
| Debt Non-Current | 3.27M | ||
| Total Liabilities | 24.75M | ||
| Accumulated Retained Earnings (Deficit) | -613.44M | ||
| Accumulated Other Comprehensive Income | -107.00K | ||
| Shareholders Equity | 102.24M | ||
| Shareholders Equity (USD) | 102.24M | ||
| Assets Non-Current | 4.24M | ||
| Total Debt (USD) | 4.26M | ||
| Liabilities Non-Current | 3.27M | ||
| Trade and Non-Trade Payables | 5.25M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 51.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -2.29M | ||
| Capital Expenditure | -6.00K | ||
| Net Cash Flow from Investing | 18.26M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 18.27M | ||
| Net Cash Flow from Operations | -29.63M | ||
| Share Based Compensation | 1.81M | ||